GHRP-2

5mg Vial

2 September 2026Updated 2 September 2026

GHRP-2

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for GHRP-2.

Create free account Member login

Full range of benefits for GHRP-2

Stimulates pulsatile growth hormone (GH) secretion via ghrelin receptor activation

Can increase circulating IGF-1 levels indirectly through GH rise

May enhance appetite and caloric intake by mimicking ghrelin

May support increased lean mass and muscle protein synthesis

May assist fat loss when combined with diet and exercise

May improve sleep architecture via GH-related mechanisms

May promote tissue repair and wound healing through anabolic effects

Reduces somatostatin-mediated suppression of GH secretion

Used experimentally to assess GH axis function in research and clinics

Can increase gastric motility and promote gastric emptying

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(4)Compatible(3)Monitor(4)Avoid(4)

Not recommended for concurrent use

Recombinant human growth hormone (rhGH)

Concurrent rhGH and GHRP-2 can cause additive GH/IGF‑1 excess with increased risk of adverse effects (edema, glucose intolerance), so combination should be carefully justified and monitored.

Ghrelin receptor agonists (ibutamoren/MK-677)

Combining GHRP-2 with other ghrelin receptor agonists may produce excessive GH secretion and metabolic side effects, so clinicians should avoid or closely evaluate dual use.

Active or recent malignancy

Because GH/IGF‑1 signalling can promote cellular proliferation, GHRP-2 should be used with caution in patients with active or recently treated cancers and requires oncology input.

Estrogen therapy (oral/conjugated estrogens)

Estrogens alter GH and IGF‑1 dynamics (especially oral estrogens increasing GH but lowering IGF‑1) and may confound response assessment and metabolic risk during GHRP-2 treatment.

All interaction categories

Synergistic (4)

CJC-1295 (GHRH analog): Combining GHRP-2 with a GHRH analog like CJC-1295 synergistically increases amplitude and duration of pulsatile GH release by stimulating both hypothalamic and pituitary pathways.
Sermorelin (GHRH): Sermorelin co‑administration augments GH secretion when given with GHRP-2 by providing complementary GHRH-driven pituitary stimulation.
Tesamorelin: As a long‑acting GHRH analog, tesamorelin can potentiate GHRP-2 effects on GH release and IGF‑1 production when clinically indicated.
Arginine (oral/IV): Arginine suppresses somatostatin tone and can amplify the GH secretory response to GHRP-2 when used adjunctively in stimulation protocols.

Compatible (3)

BPC-157: BPC-157 has a distinct tissue‑repair mechanism and no known direct pharmacodynamic interaction with GHRP-2, allowing co‑administration without specific adjustment.
Thymosin beta‑4 (TB-500): Thymosin beta‑4 acts on wound healing and cell migration via different pathways from GHRP-2 and is generally neutral when co‑administered under supervision.
Vitamin D supplementation: Vitamin D has no direct interaction with GHRP-2 pharmacology and can be continued without specific alteration related to GHRP-2 therapy.

Monitor (4)

Insulin and oral hypoglycaemic agents: GHRP-2 increases GH and can induce insulin resistance or hyperglycaemia, so glucose control and antidiabetic dosing should be monitored and adjusted as needed.
Systemic corticosteroids: Glucocorticoids antagonize GH action and impair GH secretion while worsening glycaemic control, necessitating monitoring of therapeutic response and glucose levels.
Somatostatin analogs (octreotide, lanreotide): Somatostatin analogs blunt GH release and can markedly reduce the efficacy of GHRP-2, requiring monitoring and possible dose/timing adjustments.
Thyroid hormone replacement: Thyroid status influences GH responsiveness and IGF‑1 levels, so initiation or adjustment of levothyroxine during GHRP-2 therapy warrants monitoring of GH/IGF‑1 and clinical response.

Avoid (4)

Recombinant human growth hormone (rhGH): Concurrent rhGH and GHRP-2 can cause additive GH/IGF‑1 excess with increased risk of adverse effects (edema, glucose intolerance), so combination should be carefully justified and monitored.
Ghrelin receptor agonists (ibutamoren/MK-677): Combining GHRP-2 with other ghrelin receptor agonists may produce excessive GH secretion and metabolic side effects, so clinicians should avoid or closely evaluate dual use.
Active or recent malignancy: Because GH/IGF‑1 signalling can promote cellular proliferation, GHRP-2 should be used with caution in patients with active or recently treated cancers and requires oncology input.
Estrogen therapy (oral/conjugated estrogens): Estrogens alter GH and IGF‑1 dynamics (especially oral estrogens increasing GH but lowering IGF‑1) and may confound response assessment and metabolic risk during GHRP-2 treatment.